Image

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Recruiting
18 years of age
Both
Phase 3

Powered by AI

Overview

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.

Eligibility

Inclusion Criteria for the Surveillance Phase:

  • Histologically confirmed MIUC (also termed TCC) of the bladder
  • TNM classification (based on AJCC Cancer Staging Manual, 8th Edition; Amin et al. 2016) at pathological examination of surgical resection specimen as follows: For patients treated with prior NAC: tumor stage of ypT2-4a or ypN+ and M0. For patients who have not received prior NAC: tumor stage of pT2-4a or pN+ and M0
  • Surgical resection of MIUC of the bladder
  • Patients who have received prior platinum-based NAC.
  • Patients who have not received prior platinum-based NAC, have refused, are ineligible ("unfit") for cisplatin-based adjuvant chemotherapy, or will not receive based on physicisan's decision.
  • ctDNA assay developed based on tumor tissue specimen and matched normal DNA from blood.
  • Tumor PD-L1 expression per IHC that is evaluable by central testing of a representative tumor tissue specimen.
  • Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan of the pelvis, abdomen, and chest no more than 4 weeks prior to enrollment.
  • Full recovery from cystectomy and enrollment within 24 weeks following cystectomy. Minimum of 6 weeks must have elapsed from surgery.

Additional Inclusion Criteria for the Treatment Phase:

  • Blood for plasma ctDNA sample evaluated to be ctDNA positive, defined as the presence of two or more mutations out of the 16 mutations identified based on patient's WES evaluable (ctDNA assay designability) report
  • Absence of residual disease and absence of metastasis, as confirmed by a negative baseline CT or MRI scan of the pelvis, abdomen, and chest no more than 28 days prior to randomization, as assessed by the investigator
  • ECOG Performance Status of <= 2
  • Life expectancy >=12 weeks
  • Adequate hematologic and end-organ function, investigator decision
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs

General Medical Exclusion Criteria for the Surveillance Phase:

  • Known PD-L1 IHC result for adjuvant therapy. The decision for the adjuvant therapy should not be based on the PD-L1 IHC result. If a cap is in effect limiting enrollment of PD-L1 negative patients, this exclusion criterion will not apply.
  • Pregnancy or breastfeeding
  • Positive test for HIV, with the following exception: Patients with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy, have a CD4 count >= 200/µL, and have an undetectable viral load
  • Patients with active hepatitis B virus or hepatitis C. Patients with past HBV infection or resolved HBV infection are eligible. A negative HBV DNA test must be obtained in these patients prior to enrollment.
        Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase
        chain reaction is negative for HCV RNA.
          -  Active tuberculosis confirmed by a test performed within 3 months prior to treatment
             initiation.
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins
          -  Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
             or any component of the atezolizumab formulation
          -  History of autoimmune disease. Patients with a history of autoimmune-related
             hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for
             this study. Patients with controlled Type I diabetes mellitus on a stable dose of
             insulin regimen may be eligible for this study.
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is
             permitted.
          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease
             (Class II or greater), myocardial infarction within the previous 3 months, unstable
             arrhythmias, or unstable angina
        Cancer-Specific Exclusion Criteria for the Surveillance Phase:
          -  Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3
             weeks prior to study enrollment
          -  Adjuvant chemotherapy or radiation therapy for UC following cystectomy
          -  Treatment with any other investigational agent or participation in another clinical
             trial with therapeutic intent within 28 days or 5 half-lives of the drug, whichever is
             longer, prior to enrollment
          -  Malignancies other than UC within 5 years prior to study enrollment
        Additional Exclusion Criteria for the Treatment Phase:
          -  Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3
             weeks prior to randomization to the treatment phase Hormone-replacement therapy or
             oral contraceptives are allowed.
          -  Adjuvant chemotherapy or radiation therapy for UC following cystectomy
          -  Treatment with any other investigational agent or participation in another clinical
             trial with therapeutic intent within 28 days or 5 half-lives of the drug, whichever is
             longer, prior to randomization to the treatment phase
          -  Positive test for HIV, with the following exception: Patients with a positive HIV test
             at screening are eligible provided they are stable on antiretroviral therapy, have a
             CD4 count >= 200/μL, and have an undetectable viral load.
          -  Patients with active hepatitis B virus or hepatitis C
          -  Active tuberculosis confirmed by a test performed within 3 months prior to treatment
             initiation

Study details

Muscle-invasive Bladder Cancer

NCT04660344

Hoffmann-La Roche

8 June 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.